Medic Vision: ‘Only FDA-cleared 3rd Party XR-29 Solution at RSNA’
Medic Vision will present at RSNA 2016 its XR-29 solution.
Medic Vision Imaging Solutions will present at RSNA 2016 their FDA-cleared SafeCT-29.
SafeCT-29 is the first and only FDA-cleared third party XR-29 solution that helps meet the NEMA XR-29 (Smart Dose) standard, according to a release. Practices that meet the standard can avoid a CMS penalty, which will rise to 15% in 2017 for non-compliant scanners.
SafeCT-29 is CT-vendor neutral and offers full compliance with all of the XR-29 Dose Check and RDSR requirements, according to the release. The system is fully automatic and enables the technologist to maintain their existing workflow, the release said, it connects to the CT console, analyzes data in real time, and alerts the operator if the dose is too high. After the scan, SafeCT-29 generates Radiation Dose Structured Reports, as required by the XR-29 standard, the release said.
Medic Vision will be at booth 7938.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
